Department of Nephrology, The First Hospital of Jilin University, Changchun, 130021, Jilin, People's Republic of China.
Department of Thyroid Surgery, The First Hospital of Jilin University, Changchun, 130021, Jilin, People's Republic of China.
Arch Virol. 2021 Aug;166(8):2071-2087. doi: 10.1007/s00705-021-05012-2. Epub 2021 Apr 2.
Coronavirus disease 2019 (COVID-19), defined by the World Health Organization (WHO), has affected more than 50 million patients worldwide and caused a global public health emergency. Therefore, there is a recognized need to identify risk factors for COVID-19 severity and mortality. A systematic search of electronic databases (PubMed, Embase and Cochrane Library) for studies published before September 29, 2020, was performed. Studies that investigated risk factors for progression and mortality in COVID-19 patients were included. A total 344,431 participants from 34 studies were included in this meta-analysis. Regarding comorbidities, cerebrovascular disease (CVD), chronic kidney disease (CKD), coronary heart disease (CHD), and malignancy were associated with an increased risk of progression and mortality in COVID-19 patients. Regarding clinical manifestations, sputum production was associated with a dramatically increased risk of progression and mortality. Hemoptysis was a risk factor for death in COVID-19 patients. In laboratory examinations, increased neutrophil count, decreased lymphocyte count, decreased platelet count, increased C-reactive protein (CRP), coinfection with bacteria or fungi, increased alanine aminotransferase (ALT) and creatine kinase (CK), increased N-terminal pronatriuretic peptide (NT-proBNP), and bilateral pneumonia in CT/X-ray were significantly more frequent in the severe group compared with the non-severe group. Moreover, the proportion of patients with increased CRP and total bilirubin (TBIL) was also significantly higher in the deceased group than in the survival group. CVD, CKD, sputum production, increased neutrophil count, decreased lymphocyte count, decreased platelet count, increased CRP, coinfection with bacteria or fungi, increased ALT and CK, increased NT-proBNP, and bilateral pneumonia in CT/X-ray were associated with an increased risk of progression in COVID-19 patients. Moreover, the proportion of patients with increased sputum production, hemoptysis, CRP and TBIL was also significantly higher in the deceased group.
新型冠状病毒病(COVID-19),由世界卫生组织(WHO)定义,已影响全球超过 5000 万患者,并引发全球公共卫生紧急事件。因此,人们认识到需要确定 COVID-19 严重程度和死亡率的危险因素。对 2020 年 9 月 29 日前发表的电子数据库(PubMed、Embase 和 Cochrane Library)进行了系统检索。纳入了研究 COVID-19 患者进展和死亡危险因素的研究。这项荟萃分析共纳入了来自 34 项研究的 344431 名患者。在合并症方面,脑血管疾病(CVD)、慢性肾脏病(CKD)、冠心病(CHD)和恶性肿瘤与 COVID-19 患者的进展和死亡风险增加相关。在临床表现方面,咳痰与进展和死亡风险显著增加相关。咯血是 COVID-19 患者死亡的危险因素。在实验室检查方面,中性粒细胞计数增加、淋巴细胞计数减少、血小板计数减少、C 反应蛋白(CRP)增加、细菌或真菌感染合并症、丙氨酸氨基转移酶(ALT)和肌酸激酶(CK)增加、N 端脑利钠肽前体(NT-proBNP)增加以及 CT/X 射线的双侧肺炎在重症组中比非重症组更为常见。此外,CRP 和总胆红素(TBIL)增加的患者在死亡组中的比例也明显高于存活组。CVD、CKD、咳痰、中性粒细胞计数增加、淋巴细胞计数减少、血小板计数减少、CRP 增加、细菌或真菌感染合并症、ALT 和 CK 增加、NT-proBNP 增加以及 CT/X 射线的双侧肺炎与 COVID-19 患者的进展风险增加相关。此外,在死亡组中,咳痰、咯血、CRP 和 TBIL 增加的患者比例也明显更高。